AZN241213C95000
- 0.00
- 0.000.00%
AstraZeneca Newsroom
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
"Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News
United Kingdom's National Health Service Drug Spending Priorities Questioned in New Analysis
AstraZeneca's COVID-19 Prevention Drug Kavigale Secures EU Panel's Positive Opinion
AstraZeneca (AZN) Gets a Hold From Kepler Capital
Tracer Biotechnologies Announces Multi-Year Project With AstraZeneca
Tracer Biotechnologies Announces Agreement for Next-Generation Cancer Monitoring for Drug Development
Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study
TD Cowen Maintains AstraZeneca(AZN.US) With Buy Rating, Announces Target Price $95
TD Cowen Keeps Their Buy Rating on AstraZeneca (AZN)
Express News | A former employee of Amoy Diagnostics has been sentenced to prison for being involved in a fraud case with AstraZeneca employees.
AstraZeneca (AZN.US) and MSD (MRK.US) announce long-term results from phase 3 Olympia clinical trial
Lynparza is a “first-in-class” PARP inhibitor and the first synthetic lethal targeted therapy to target cells/tumors with homologous recombinant repair (HRR) defects (such as cells carrying BRCA1 and/or BRCA2 mutations).
AstraZeneca, Merck Report Positive Long-term Data for Lynparza
Lynparza Shows Significant Survival Benefit In Early Breast Cancer In OlympiA Phase III Trial; Reduces Risk Of Death By 28% And Recurrence By 35% At Six Years, Becoming First PARP Inhibitor To Improve Survival In Early Breast Cancer
LYNPARZA (Olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase III Trial
Lynparza Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase III Trial
Why Astrazeneca (AZN) Is a Top Value Stock for the Long-Term
AZN, Daiichi's ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC
AstraZeneca (AZN) Receives a Hold From Jefferies
Astrazeneca (AZN.US) has achieved breakthrough therapy designation for a potential blockbuster ADC.
Astrazeneca (AZN.US) has a potential blockbuster ADC that has been granted breakthrough therapy designation.